Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

Polatuzumab
For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Share This Post

May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

The POLARIX (NCT03274492) trial, which included 879 patients with previously untreated large B-cell lymphoma and an IPI score of 2–5, served as the foundation for the approval. The trial assessed the superiority of replacing vincristine in the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with polatuzumab vedotin. For six 21-day cycles, patients were randomly assigned (1:1) to receive either polatuzumab vedotin plus R-CHP (pola + R-CHP) or R-CHOP. Both arms then received two more cycles of rituximab alone. The most common diagnoses were HGBL (11%), NOS (84%) and de novo DLBCL.

The investigator-assessed progression-free survival (PFS) was used to determine effectiveness. PFS in the pola + R-CHP arm was statistically substantially longer, with a hazard ratio (HR) of 0.73 (95% CI: 0.57, 0.95; p = 0.0177). Modified event-free survival was significantly improved in this arm (HR 0.75; 95% CI: 0.58, 0.96; p=0.0244). In the final analysis, there was no discernible change in the complete response rate or overall survival (HR 0.94; 95% CI: 0.67, 1.33).

Aside from laboratory abnormalities, peripheral neuropathy, nausea, fatigue, diarrhoea, constipation, alopecia, and mucositis were the most frequent adverse reactions with pola + R-CHP (20%). Lymphopenia, neutropenia, hyperuricemia, and anaemia were grade 3 to 4 laboratory abnormalities (10%). In 53% of patients, peripheral neuropathy either formed or got worse, and in 58% of patients, it got better after a median of 4 months. 34% of patients experienced serious adverse events, including pneumonia and febrile neutropenia.

In conjunction with R-CHP, the recommended dosage of polatuzumab vedotin is 1.8 mg/kg administered intravenously every 21 days for six cycles. Antihistamine, antipyretic, and prophylactic granulocyte colony-stimulating factor administration to patients is advised.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy